Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of BKM120 in advanced or metastatic differentiated thyroid cancer
2012-003814-15Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in follicular carcinoma (FTC) and thyroid cancer, sponsored by Hospices Civils de Lyon. Primary endpoint: Progression-free survival at 6 months. Started Jun 2013; status: completed.
02
Drugs
buparlisib
03
Conditions
follicular carcinoma (FTC)thyroid cancer
Beyond the preview
Go deeper on 2012-003814-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003814-15.